INTRODUCTION
============

Colorectal cancer is one of the most common cancers in Korea as well as in western countries and its incidence is increasing. Major organs of distant metastases from colorectal cancer are liver, lung, and bone.[@B1] There is no accurate report on the incidence of hepatic metastases in our country, but the main cause of death from colorectal cancer is associated with hepatic metastases.[@B2] In the North America, the incidence of hepatic metastases has been reported as 15-25% in the synchronous, 25-50% in the metachronous.[@B3][@B4][@B5]

Hepatic resection has been regarded as a safe and effective treatment option in patients with hepatic metastasis from colorectal cancer. Hepatic resection can be accomplished with an associated surgical mortality rate uniformly less than 5%, even for resection of as much as 80% of the liver.[@B6][@B7][@B8][@B9] In general, the median survival period for untreated patients with hepatic metastases from colorectal cancer is 6-12 months and 12-18 months for patients treated with chemotherapy alone. On the other hand, complete resection of detected hepatic metastases results in a 5-year survival for one third of patients even in the era that current adjuvant chemotherapy had not been established. A recent series reported a nearly 60% 5-year survival rate when combined with modern neoadjuvant and adjuvant chemotherapy and other ablation therapies.[@B10][@B11]

Many investigators have identified clinical variables that predict long-term survival after hepatic resection in patients with hepatic metastases from colorectal cancer. Factors commonly associated with adverse outcomes have been primary tumor stage, regional nodal positivity, synchronous presentation of metastatic tumors, disease-free survival, number of metastatic tumors, bilateral tumors, size of the tumor, carcinoembryonic antigen (CEA) level on the diagnosis of hepatic metastasis, positive resection margins, extrahepatic disease.[@B12][@B13][@B14] Several investigators have attempted to develop a scoring system using these clinical variables. But such clinical scoring systems have not been widely used.

In this study, we attempted to make a useful clinical risk scoring system using clinical and pathologic variables for predicting recurrence after hepatic resection for colorectal cancer with hepatic metastasis.

METHODS
=======

Of the 402 patients who underwent hepatectomy for hepatic metastases from colorectal cancer between March 1994 and February 2009 at the department of surgery, Chonbuk National University Hospital, 150 were selected for the study. We excluded the 252 patients who did not receive surgery for a primary cancer lesion, who had multiorgan distant metastasis, who died due to surgical complications, who had a history of cancer at another site, or who had an insufficient medical record.

We studied 14 factors as followed: gender, age, primary tumor location, primary tumor stage, primary tumor pathologic grade, regional nodal positivity, number of metastatic lesions, distribution of metastatic lesions, tumor size of the largest hepatic metastasis, total size of hepatic metastases, CEA and CA19-9 levels, temporal relationship, and extrahepatic lesions.

Univariate analysis, multivariate analysis, Kaplan-Meier method, and Cox proportional hazard regression analysis were performed using SPSS (ver. 17).

RESULTS
=======

Mean age at the time of diagnosis was 60.9 years (range: 27-84) and 105 (70.0%) were men. Median follow-up was 27.2 months. The rectum was the most common primary tumor site (n=81; 54.0%). The most common initial primary tumor stage was stage IV (n=89; 59.3%), and there were 2 patients with stage I ([Table 1](#T1){ref-type="table"}).

The overall survival rate was 83% at 1 year after hepatic resection and 35.9% at 5 years. All patients with stage I colorectal cancer showed 100% survival at 1, 3 and 5 years. Survival for patients with stage II was 100% at 1 year, 79.6% at 3 years, and 42.6% at 5 years; for patients with stage III disease, survival was 93.8% at 1 year, 71.8% at 3 years, and 57.1% at 5 years; for stage IV, it was 72.7% at 1 year, 46.3% at 3 years, and 29.4% at 5 years (*p*\<0.001) ([Fig. 1](#F1){ref-type="fig"}).

Hepatic metastases discovered within 12 months after primary colorectal resection was defined as a synchronous metastasis; after 12 months, it was defined as metachronous. Comparison of survival between synchronous and metachronous metastatic tumors were significant: 78.8% at 1 year, 49.4% at 3 years, and 23.3% at 5 years for synchronous tumors, and 100% at 1 year, 96% at 3 years, and 77.5% at 5 years for metachronous tumors ([Fig. 2](#F2){ref-type="fig"}).

Gender, age, primary tumor grade, and primary tumor location were not significant in univariate analysis. Primary tumor stage (stage IV), CEA level on the diagnosis of hepatic metastasis (\>10 ng/ml), CA19-9 level on of hepatic metastasis (\>36 U/ml), synchronous metastasis, extrahepatic metastasis, bilobar hepatic metastasis, number of metastatic lesion (≥3), the largest hepatic metastasis tumor size (\>5 cm), and the total size of hepatic metastases (\>10 cm) were associated with significantly poorer prognosis in univariate analysis ([Table 2](#T2){ref-type="table"}). Among the factors that predicted poor outcomes, synchronous metastasis and CEA level on diagnosis of hepatic metastasis (\>10 ng/ml) were significant in both univariate and multivariate analyses ([Table 3](#T3){ref-type="table"}).

By assigning 1 point for each of the 9 significant factors in univariate analysis and adding the scores yielded total scores from 0 to 9 points. Using this scoring system, we divided patients into three groups: Scores of 0 to 2 were group A, 3 to 5 were group B, and 6 to 9 were group C. Groups were compared for long-term survival rates. In the case of group C, median survival was 15 months and the survival rate was 57.4% at 1 year after hepatic resection; there were no patients with long-term survival over 3 years ([Table 4](#T4){ref-type="table"}).

DISCUSSION
==========

The liver is the first major organ reached by venous blood draining from the gastrointestinal tract. Cancer cells traveling by hematogenous spread, therefore, have a high likelihood of arriving and lodging within the liver. This would explain the observation that the liver is the most common organ of distant metastases from colorectal cancer.[@B15]

In the past, hepatic resection was regarded with great skepticism.[@B16] However, the evolution of liver surgery uniformly lowered the mortality rate and made possible extensive hepatic resection. Until recently, according to many reports on patients with liver metastasis of colorectal cancer, hepatic resection has been established as a safe and effective treatment that leads to a relatively high long-term survival.[@B17][@B18][@B19]

Many studies have reported clinical risk scoring systems that consist of clinical and pathologic factors and are helpful for predicting long term survival ([Table 5](#T5){ref-type="table"}). Gayowski et al.[@B18] included size and distribution of tumors and proposed a staging system for hepatic colorectal metastases based on the size of liver metastases (\>2 cm), number of lesions (\>1), and bilobar distribution of tumors. Cady et al.[@B20] proposed a scoring index based on four risk factors: disease-free interval after treatment of the primary tumor, number of liver tumors (\>4), CEA level, and margin of resection. Nordlinger et al.[@B21] attempted to incorporate additional prognostic criteria for outcomes and proposed a system based on seven criteria: age \>60 years, stage of the primary tumor, \>4 liver metastases, synchronous disease, size of the largest lesion \>5 cm, CEA level \>30 ng/ml, and positive margins.

Fong et al.[@B12] found seven criteria to be independent prognostic factors for outcomes. However, except for the presence of extrahepatic disease and a positive surgical margin, their other five criteria-nodal status of the primary tumor, disease-free interval from diagnosis of the primary tumor to discovery of the liver metastases (\<12 months), number of tumors (\>1), preoperative CEA level \>200 ng/ml, and size of the largest tumor \>5 cm - were incorporated into a proposed clinical risk scoring system.

Our risk scoring system included the clinical and pathological factors listed above, and other factors (CA19-9, primary tumor grade). As well using our scoring system, group A had good prognosis compared with the other groups. Survival in group A was 94% at 1 year, 81% at 3 years, and 55% at 5 years. Furthermore, 5-year survival rate in group C, which scored over 6 points, was 0%. Therefore, if the score after surgery is over 3 points (groups B and C group, a more aggressive chemotherapy is necessary.

Due to recent developments in molecular genetic analysis, more sophisticated markers, such as tumor ploidy, oncogene expression, or tumor suppressor gene expression, may further stratify patients with regard to outcome.[@B20][@B21] However, such molecular or genetic markers are not likely to be readily available except at a few academic centers; this limits their usefulness and also dooms any system incorporating their use in terms of wide applicability.

In conclusion, CEA \>10 ng/ml and metachronous metastases had significance in both univariate and multivariate analyses among nine criteria. All nine criteria were used in our risk scoring system. We assigned one point for each criterion and divided all cases into three groups. The risk scoring system devised in this study for patients with hepatic metastases from colorectal cancer is relatively simple and may enable us to accurately predict the outcomes.
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![Cumulative survival curves of the groups as related to the stages. 1-, 3-, and 5-year survival rate was all 100% in stage I (n=2). 1-, 3-, and 5-year survival rate was 100%, 79.6%, and 42.6% each in stage II (n=27). 1-, 3-, and 5-year survival rate was 93.8%, 71.8%, and 57.1% each in stage III (n=32). 1-, 3-, and 5-year survival rate was 72.7%, 46.3%, and 29.4% each in stage IV (n=89) (*p*\<0.001).](kjhbps-15-146-g001){#F1}

![Cumulative survival curves of the groups between synchronous and metachronous metastasis. The 1-, 3-, and 5-year survival rate was 78.8%, 49.4%, and 23.3% each in synchronous (n=122) and 1-, 3-, and 5-year survival rate was 100%, 96%, and 77.5% each in metachronous (n=28), respectively (*p*\<0.001).](kjhbps-15-146-g002){#F2}

###### Primary tumor stage of patients with colorectal cancer
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###### Significant prognostic factors for survival in patients with hepatic metastasis after primary colorectal resection by univariate analysis
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###### Significant prognostic factors for survival in patients with hepatic metastasis after primary colorectal resection by multivariate analysis
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###### Comparison of survival rates for groups related to clinical risk scoring system
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###### Predictors of recurrence after hepatic resection for metastatic colorectal cancer
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N, no; Y, yes.
